Clinical

Articles

In the third year of treatment, both dose cohorts did not experience any contrast-enhancing lesions, and only a small population in the Barcelona center showed new T2 lesions.

Low-Dose Rituximab Safe, as Effective as High Dose in MS

The medical director manager of neuroscience at Genentech discussed the swath of data presented on the humanized anti-CD20 monoclonal antibody at MS Virtual.

Ocrelizumab Shows Range of Benefits for Spectrum of Patients With Multiple Sclerosis

Videos

The neurology resident at NYU Langone shared her thoughts on the need for publication of clinician-based data and why maintaining a high level of mental health remains a top priority during the COVID-19 pandemic. 

Leah Croll, MD: Importance of Mental Health of Clinicians During COVID-19 Pandemic

Early intensive treatment was more effective in controlling disability progression over time compared with an escalation therapy approach.

Early Intensive MS Treatment Yields Better Outcomes Than Escalation Approach

The director of the UCSF Weill Institute for Neuroscience spoke to the advantages of having agents that can be used across the spectrum of MS, and the role disease progression plays early on.

Stephen L. Hauser, MD: Increasing Understanding of Disease Progression in MS

Patients with lower levels of disability tended to report fatigue as the most impactful symptom in daily life.

Multiple Sclerosis

New content coming soon, please check back later.